To obtain a deeper insight into the model genes in GC onset and progression, patients were divided into three groups according to the expression levels of SNCG, MATN3, DDO, ITGAD, FGF8, and ABCB5 in their tumor samples: low-risk (LR) (HCC01, HCC05, HCC05, HCC06, HCC07), median risk (MR) (HCC03, HCC08, HCC09, HCC10), high-risk (HR) (HCC02, HCC04)) (Figure S2F). This evidence concerns the gene MATN3 and neoplasm.